Daiwa Securities Group Inc. Invests $88,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Daiwa Securities Group Inc. acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Rating) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 5,114 shares of the company’s stock, valued at approximately $88,000.

Several other institutional investors have also bought and sold shares of RXRX. Morgan Stanley bought a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $41,000. Royal Bank of Canada bought a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $53,000. Bank of America Corp DE bought a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $288,000. Invesco Ltd. bought a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $205,000. Finally, Strs Ohio increased its stake in shares of Recursion Pharmaceuticals by 34.7% in the third quarter. Strs Ohio now owns 6,600 shares of the company’s stock worth $151,000 after purchasing an additional 1,700 shares during the period. Institutional investors and hedge funds own 37.71% of the company’s stock.

In other news, CEO Christopher Gibson sold 19,858 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Monday, January 31st. The shares were sold at an average price of $11.73, for a total value of $232,934.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 891,401 shares of company stock valued at $6,586,664 in the last quarter.

NASDAQ RXRX opened at $6.00 on Friday. The stock’s 50 day moving average is $7.92 and its two-hundred day moving average is $13.73. The company has a market capitalization of $1.02 billion and a price-to-earnings ratio of -2.61. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.80 and a 1-year high of $42.81.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Rating) last released its quarterly earnings data on Wednesday, March 23rd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). The company had revenue of $2.53 million for the quarter, compared to analyst estimates of $7.62 million. Recursion Pharmaceuticals had a negative net margin of 1,832.18% and a negative return on equity of 48.07%. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -0.95 EPS for the current year.

A number of equities research analysts recently weighed in on RXRX shares. Bank of America downgraded Recursion Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $10.00 target price on the stock. in a research report on Monday, April 18th. SVB Leerink downgraded Recursion Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $32.00 to $10.00 in a research report on Friday, March 4th. The Goldman Sachs Group decreased their target price on Recursion Pharmaceuticals from $32.00 to $10.00 and set a “neutral” rating on the stock in a research report on Thursday, March 24th. Finally, Zacks Investment Research raised Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, March 16th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $22.14.

About Recursion Pharmaceuticals (Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development.

Further Reading

Institutional Ownership by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.